Læknaneminn - 01.04.2002, Blaðsíða 9

Heimildir
1 Levy D, Larson MG, Vasan RS, Kannel WB, Ho KKL.
The progression from hypertension to congestive heart
failure. JAMA 1996; 275:1557-162.
2 Working Group on Primary Prevention of Hyper-
tension. Working Group Report on Primary Prevention
of Hypertension: National High Blood Pressure Ed-
ucation Program: National Institutes of Health, 1993.
3 Segall HN. How Korotkoff, the surgeon, discover-
ed the auscultatory method of measuring arterial
pressure. Ann Internal Med 197583:561-562.
4 Samani NJ. Molecular genetics of susceptibility to
the development of hypertension. Br Med Bull
1994;50260-271
5 Wiliams RR, Hunt SC, Hopkins PN, et al. Genetic
basis of familial dyslipidemia and hypertension: 15-
year results from Utah. Am J Hypertens 1993;6:319S-
327S.
6 Muntzel M, Drueke T. A comprehensive review of
the salt and blood pressure relationship. Am J Hyper-
tens 1992;5:1S-42S.
7 Midgley JP, Matthew AG, Greenwood CMT, Logan
AG. Effect of reduced dietary sodium on blood
pressure; a meta-analysis of randomized controlled tri-
als. JAMA 1996;275:1590-1597.
8 Sacks FM, Svetkey LP, Vollmer WM, et al. Effects
on blood pressure of reduced dietary sodium and the
dietary approaches to stop hypretension (DASH) diet.
N Engl .1 Med;344:3-10.
9 Johnson CJ. Renin-angiotensin system: A dual tis-
sue and hormonal system for cardiovascular control. J
Hypertens 1992; 10:S 13-S26.
10 PickeringTG. Does psychological stress contribu-
te to the development of hypertension and coronary he-
art disease? Eur J Clin Pharmacol 1990;39:S1-S7.
11 Dzau VJ, Gibbons GH, Cooke JP, Omoigui N.
Vascular biology and medicine in the 1990's: Scope,
concepts potentials, and perspectives. Circulation
1993;87:705-719.
12 Haffner SM, Ferrannini E, Flazuda HP, Stern MP.
Clustering of cardiovascular risk in confirmed
prehypertensive individuals. Hypertension 1992;20:38-
45.
13 Reaven GM, Chen Y-DI. Insulin resistence, its
consequences, and coronary heart disease; Must we
choose one culprit? Circulation 1996;93:1780-1783.
14 The Fifth Report of the Joint National Committee
on Detection, Evaluation, and Treatment of High Blood
Pressure. Arch Intern Med 1993;153:154-183.
15 Sprafka JM, Strickland D, Gomez-Marin O, Prine-
as RJ. The effect of cuff size on blood pressure mea-
surement in adults. Epidemiology 1991;2:214-217.
16 Matangi M, Angus D, Brouillard D. White coat
systolic hypertension; definition and prevalence by 24
hour ambulatory blood pressure monitoring. Can J
Cardiol 2001; 17:119C.
17 Mathieu G, Biron P, Roberge F, Pickard JM, Gou-
let C, Allard C. Blood pressure determinations during
medical examinations: How many? Can J Publ Health
1974;65:447-450.
18 The Trials of Hypertension Prevention Colla-
borative Research Group. The effects of nonp-
harmacologic interventions on blood pressure of per-
sons with high normal levels: Results of the Trials of
Hypertension Prevention, Phase I. jama 1989:262; 1801-
1807.
19 National High Blood Pressure Education Program
Working Group. National High Blood Pressure Ed-
ucation Program Working Group Report on Primary
Prevention of Hypertension. Arch Intern Mcd
1993;153:186-208.
20 Effect of metoprolol CR/XL in chronic heart
failure: Metoprolol CR/XL Randomised Inter-
vention Trial inCongestive Heart Faiiure (MERIT-HF)
Lancet 1999;353:2001-2007.
21 Effect of enalapril on survival in patients witli red-
uced left ventricular ejection fractions and congestive
heartfailure. N Engl J Med 1991;325:293-302.
22 Yusuf S. Effects of an angiotensin-converting-
enzyme inhibitor, ramipril, on cardiovascular events in
high-risk patients. N Engl J Med 2000; 342(3): 145-153
23 HOPE study investigators. Effects of ramipril on
cardiovascular and microvascular outcomes in people
with diabetes mellitus: results of the HOPE study and
MICRO-HOPE study. Lancet 2000; 355: 253-259
24 Brenner BM, Cooper ME, de Zeeuw D, Keane WF,
Mitch WE, Parving HH, Remuzzi G, Snappinn SM,
Zhang Z, Shaninfar S for the RENAAL Investigators.
Effects of losartan oti renal and cardiovascular
outcomes in patients with type 2 diabetes and
nephropathy. N Eng .1 Med 2001;345:861-869.
25 Dahlöf B, Devereux RB, Kjeldsen SE, et al.
Cardiovascular morbidity and mortality in the Losartan
Intervention For Endpoint reduction in hypertension
study (LIFE): a randomized trial against atenolol.
Lancet 2002; 359(9311 ):995-1003.
26 Pansa JA. High-normal blood pressure-more
„high“ than „normal“. N Engl J Med 2001 ;345:1337-
1339.
27 Hansson L, et al. Randomized trial of old and new
antihypertensive drugs in elderly patients: cardiovascul-
ar mortality and morbidity in the Swedish Trial in Old
Patients witli Hypertension-2 study. The Lancet
1999;354:1751-1756
7